Al-Ali, Hussein N.
Crichton, Scott J.
Fabian, Charlene
Pepper, Chris http://orcid.org/0000-0003-3603-8839
Butcher, David R. http://orcid.org/0009-0000-6059-3619
Dempsey, Fiona C.
Parris, Christopher N. http://orcid.org/0000-0002-6347-863X
Article History
Received: 13 July 2023
Revised: 27 November 2023
Accepted: 5 December 2023
First Online: 10 January 2024
Competing interests
: For authors CNP, HNA-A, DRB, and CP, there are no competing interests to declare. For authors, FCD, SJC, and CF; it is declared that these authors are employees or former employees (CF) of the company Medannex Ltd, Edinburgh, Scotland, UK. Medannex holds the commercial rights and associated intellectual property for the anti-annexin-A1 monoclonal antibody MDX-124. Moreover, authors FCD and SJC are shareholders in Medannex Ltd.